• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]

byJudith KandelandSarah Stapleton
April 22, 2015
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Researchers developed a small interfering RNA (siRNA) molecule targeting antithrombin (AT) production, ALN-AT3, which reduced AT concentrations in mice and monkeys when administered subcutaneously.

2. Several animal hemophilia models showed that prophylactic treatment with ALN-AT3 resulted in decreased bleeding time, increased clot sizes, and greater thrombin production as compared to controls.

Evidence Rating Level: 2 (Good)           

Study Rundown: Hemophilia is an inherited bleeding disorder characterized by a deficiency in clotting factor VIII (hemophilia A; HA) or factor IX (hemophilia B; HB). Both factors ultimately contribute to the production of thrombin, which in turn catalyzes fibrin clot formation. The most common hemophilia treatment is replacement therapy, where patients are intravenously administered clotting factors, either prophylactically or to manage active bleeding. Some patients, however, develop antibodies against the replacement factors, prompting the development of a different approach.

Previous studies have indicated that coexisting bleeding disorders that promote clotting, such as factor V Leiden, lessen the severity of hemophilia. With this idea in mind, researchers in this study developed ALN-AT3 to promote clotting by targeting production of AT, which generally opposes thrombin activity. Weekly dosages of ALN-AT3 appeared to lower AT levels for the duration of the 30-day experiment. Using a mouse model of HA, researchers found mice treated weekly with ALN-AT3 showed dose-dependent decreased clotting times and increased clot sizes in as compared to controls. HA mice treated with ALN-AT3 also had significantly improved survival times compared to untreated controls over a 26-week period, and no toxicity was found in HA mice across all ALN-AT3 dose levels. A similar non-human primate model of induced HA showed increased thrombin production in animals treated with ALN-AT3.

The novel approach used here to treat hemophilia circumvents the possibility of antibody production in response to replacement factors. Additionally, its subcutaneous availability and long-lasting effect suggest it may present a less invasive treatment method than current therapies. ALN-AT3 is in phase I clinical trials, in which it should be demonstrated the drug is safe and more effective than current treatment approaches.

Click to read the study in Nature Medicine

RELATED REPORTS

Valoctocogene roxaparvovec gene therapy efficacious for hemophilia A treatment

Recombinant viral vector treatment sustains endogenous factor IX activity in patients with hemophilia B

Lipid nanoparticles deliver messenger RNA for hemophilia B protein replacement therapy [PreClinical]

Relevant Reading: Factor V Leiden improves in vivo hemostasis in murine hemophilia models

In-Depth [animal study]: This study developed an siRNA against AT and then assessed its ability to decrease HA symptoms in mouse and monkey models of HA. Fluorogenic assays showed that depletion of AT from HA patient plasma led to increased thrombin levels in a manner dependent on depletion percentage. Combination of AT depletion paired with a standard dose of replacement factor did not elevate thrombin levels above normal levels.

To deplete AT in animals, researchers developed ALN-AT3, which delivers siRNA to hepatocytes, where AT is produced. The molecule targets a segment of the SERPINC1 transcript, which encodes AT and is preserved in rodents, monkeys and humans. Researchers began by examining ALN-AT3 pharmacokinetics and effects in wild type (WT) mice. While a single subcutaneous ALN-AT3 injection in WT mice resulted in undetectable levels of ALN-AT3 levels in plasma 4 hours later, liver levels remained detectable over multiple days. Consistent with this, nadir AT levels were achieved at around 10 days following a single dose of ALN-AT3. Repeated weekly dosages showed maintained lowered AT levels, with the lowest dose, 0.75 mg/kg, decreasing AT levels by ~80%.

Researchers then administered ALN-AT3 in mouse models of HA. HA mouse models showed 3 once-weekly doses of 3.0 mg/kg ALN-AT3 decreased coagulation times as compared to untreated mice (p<0.01, n=5 per group). In separate experiments, single doses (1-30 mg/kg) resulted in larger formed platelet and fibrin areas in treated mice when subjected to microvessel injury. High weekly doses (up to 30 mg/kg) decreased WT, but not HA mouse survival.

Large animal studies showed similar results to the mouse findings. Treating WT monkeys with 0.5 mg/kg ALN-AT3 weekly or 1 mg/kg biweekly for 8 weeks, followed by even lower weekly doses, resulted in stable 50-65% AT level reductions (n=3 per group). In monkeys injected with anti-factor VIII antibodies to induce HA, those treated weekly with 0.5 mg/kg ALN-AT3 showed greater peak thrombin levels as compared to untreated animals (p<0.01, n=4 per group).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hemophilia
Previous Post

2 Minute Medicine Rewind April 13 – April 19, 2015

Next Post

Gene therapy may be helpful for Wiskott-Aldrich Syndrome

RelatedReports

New genetic link in pulmonary arterial hypertension holds therapeutic promise
Chronic Disease

Valoctocogene roxaparvovec gene therapy efficacious for hemophilia A treatment

March 21, 2022
Chronic Disease

Recombinant viral vector treatment sustains endogenous factor IX activity in patients with hemophilia B

December 8, 2017
Blood type correlates with egg reserve in infertile women
Chronic Disease

Lipid nanoparticles deliver messenger RNA for hemophilia B protein replacement therapy [PreClinical]

June 18, 2017
Health A to Z

Patient Basics: Hemophilia

November 30, 2014
Next Post
Gene therapy may be helpful for Wiskott-Aldrich Syndrome

Gene therapy may be helpful for Wiskott-Aldrich Syndrome

PET scans in early-stage Hodgkin’s lymphoma may help guide therapy [RAPID trial]

PET scans in early-stage Hodgkin’s lymphoma may help guide therapy [RAPID trial]

Using adhesive strips with dermal sutures does not improve cosmesis

Using adhesive strips with dermal sutures does not improve cosmesis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.